Oracle Corp (NYSE: ORCL) shares rose 1.51% to $144.95 on Wednesday, outperforming a weak technology sector that fell approximately 0.8%. The stock’s relative strength came as investors reacted to the company’s expansion into healthcare artificial intelligence and maintained optimism ahead of its next earnings report.

Healthcare AI Expansion

Oracle expanded its Oracle Health Clinical AI Agent with new capabilities for clinical documentation, coding, and chart review. Available in the U.S., the updated agent suggests professional fee charge codes based on patient visits, which clinicians must review and approve before submission.

The tool also reviews electronic health records to summarize patient information, including medical history, lab results, and medications. Additionally, Oracle introduced clinician-controlled dictation, which transcribes speech directly into clinical documentation for editing.

These features build on previously announced AI tools for automated order creation. Oracle stated that its AI-powered note generation has saved physicians more than 400,000 hours across U.S. health organizations since its launch nearly two years ago.

Technical Positioning

Despite the daily gain, Oracle’s longer-term technical trend remains bearish. The stock traded 4.4% above its 20-day simple moving average (SMA) of $138.14, but remained 2.4% below its 50-day SMA of $147.81 and more than 12% below its 100-day SMA of $164.35.

A death cross formed in January, with the 50-day SMA remaining below the 200-day SMA. The relative strength index stood at 49.45, indicating neutral momentum where neither buyers nor sellers have firm control. Resistance sits near $149, close to the 50-day SMA, while support is around $135.

Earnings Outlook And Analyst Views

Analysts expect Oracle to report earnings of $1.67 per share for the quarter ending in September, up from $1.47 a year earlier. Revenue is forecast to reach $19.13 billion, compared with $14.93 billion in the prior-year period. The next earnings report is estimated for Sept. 8.

The stock carries a Buy consensus rating with an average price forecast of $258.50. Recent analyst actions include:

• UBS maintained a Buy rating on Aug. 6 but lowered its price forecast to $245.
• CLSA initiated coverage with a Hold rating and $145 price forecast on July 20.
• Bernstein maintained an Outperform rating and raised its price forecast to $325 on June 11.

Market Context And ETF Exposure

The broader market was mixed, with seven sectors advancing and an advance-decline ratio of 1.8. Health care led gains with a 2.99% increase, followed by materials at 1.80%. The Nasdaq fell 0.10%, while the S&P 500 gained 0.29%.

Oracle holds significant weightings in several technology-focused exchange-traded funds:

As a major holding, Oracle’s performance can be influenced by inflows and outflows from these funds. According to Benzinga Edge rankings, Oracle scores strongly on growth (95.91) but remains weak on momentum (6.43) and value (19.07).

What the Numbers Show

Oracle’s strong growth score (95.91) contrasts sharply with its low momentum score (6.43), reflecting a divergence between fundamental earnings expectations and current technical price action. While analysts project revenue growth from $14.93 billion to $19.13 billion, the stock remains below key moving averages, suggesting that recent gains are driven more by sector rotation and specific product news than by a reversal in broader technical trends.

Oracle's gas pipeline project in New Mexico, designed to support its data center infrastructure, has been delayed until 2027 and rerouted following earlier rejections. Bloomberg News reported the schedule change on August 14, 2026, and confirmed the rerouting plan on August 18, 2026.

Energy Transfer LP, which will construct and operate the pipeline, is now seeking to build part of the 17.8-mile conduit on land administered by the U.S. Bureau of Land Management. This shift comes after the initial plan faced rejections, necessitating a change in route to proceed with the energy supply timeline for the facility.

The delay affects the energy supply timeline for the Oracle data center infrastructure. No further details regarding the specific cause of the earlier rejections or financial implications were provided in the source reports.